{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$5.85 vs. cons $5.71",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$11.75B vs. cons $11.68B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue growth",
      "prediction": "IN-LINE",
      "answer": "pred ~3% vs. cons ~3%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guide",
      "prediction": "BETTER",
      "answer": "guide ~$24.75-25.20 midpoint vs. cons $24.90 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 organic revenue growth guide",
      "prediction": "UNCHANGED",
      "answer": "guide ~3-4% vs. cons ~3-4% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 revenue guide",
      "prediction": "UNCHANGED",
      "answer": "guide ~$47.3-48.1B vs. cons ~$47.7B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "H2/Q4 organic acceleration commentary (bioproduction + PPD)",
      "prediction": "UNKNOWN",
      "answer": "pred exit-rate ~mid-single-digit vs. cons ~4-5% (H2 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.0,
  "day5_path": "STABILIZE",
  "day5_rationale": "A modest EPS beat with the FY organic range reaffirmed and Q2 hitting the ~3% guide should deliver a relief pop given TMO's beaten-down YTD setup and the fact it held flat while Danaher fell ~11% two days prior. But the out-period math still embeds an unproven Q4 acceleration, so the market will not chase it \u2014 implicit H2 skepticism caps follow-through. Estimates hold roughly flat (small flow-through raise offset by cautious H2 modeling), so the day-1 gain largely stabilizes rather than extends or fully fades.",
  "day5_confidence": "LOW"
}